No Data
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences
Lexicon Pharmaceuticals Says Post Hoc Analysis Of Phase 3 SOLOIST-WHF Trial Shows Sotagliflozin Reduced Cardiovascular Deaths, Heart Failure Events Regardless Of Baseline Systolic Blood Pressure, Without Increase In Hypotension Or Acute Kidney Injury
Lexicon Pharmaceuticals Says Post Hoc Analysis Of Phase 3 SOLOIST-WHF Trial Shows Sotagliflozin Reduced Cardiovascular Deaths, Heart Failure Events Regardless Of Baseline Systolic Blood Pressure,
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)
Lexicon Earns Third $10M Novo Milestone
Express News | Lexicon Pharmaceuticals, - Eligible for up to $1 Bln in Upfront and Milestone Payments Plus Royalties
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment From Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1